Assertio outlines 2025 transformation priorities and maintains $108M-$123M revenue guidance while reducing legal exposure

Stock Information for Assertio Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Assertio Holdings Inc.

Assertio Reports Third Quarter 2025 Financial Results
Assertio Announces Leadership Transition
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025
Spectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: 3-DAY DEADLINE in Securities Lawsuit- Hagens Berman
DEADLINE NEXT WEEK: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Contact the Firm Before September 24, 2025
Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV
DEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025
Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.